• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors

    3/1/23 5:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email
    • Pam Marrone joins as Chairwoman of the Board of Directors and Johan de Saegher as Independent Board Member

    Elicit Plant, an agricultural biotechnology company specialized in crops' resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005582/en/

    Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant)

    Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant)

    Pam is a serial entrepreneur bringing over 30 years of leadership experience in the agricultural biologicals industry. Pam currently serves as Executive Chair of Invasive Species Control Corporation which she cofounded in 2022. Recently, she was Chief Executive Officer of Marrone Bio Innovations (MBI), an agricultural biological company she founded in 2006. In 2013, MBI listed its stock on NASDAQ. Under her leadership, the company commercialized 10 products from six EPA-registered active ingredients, and in 2019 acquired ProFarm Technologies selling bionutrient seed treatments from wood waste. Prior to establishing MBI, Marrone founded AgraQuest in 1995, where she served as CEO, Chairwoman or President until 2006. Pam is a well-recognized leader as evidenced by numerous awards, including the American Chemical Society's "Kathryn C. Hach Award for Entrepreneurial Success," "Most Admired CEO, Distinguished Career Award" by the Sacramento Business Journal, the "Sustie" award by the Ecological Farming Association, and the Natural Resources Defense Council (NRDC) Growing Green Award in the "Business Leader" category. Pam is the founder of the Biological Products Industry Alliance, now a trade group of more than 100 companies. Aside from her role as Chairwoman of Elicit Plant, Pam serves on several for-profit and non-profit Boards, including 180 Life Sciences (NASDAQ:ATNF), StemExpress, Pheronym and the Foundation for Food and Agriculture Research.

    Johan de Saegher is an accomplished business executive with 30 years of business experience of which 17 years in the crop protection industry. He currently serves as CEO of Bi-PA, a company specialized in developing innovative solutions for pest management. From 2018 to 2022 he held the position of CEO and COO of Belchim Crop Protection NV, a leading European distributor in the crop protection market, based in Belgium, with also activities in North America and Asia. Previously, and until the company was acquired by Eastman Chemical in 2014, Johan worked at Taminco (NYSE) where he held positions as Chief Operating Officer, Vice-President Agrosciences and President Asia/Latin America. He is currently also Chairman of Aphea.bio and holds a board position within Mitsui Agrisciences International.

    "I am impressed by the excellent achievements Elicit Plant has accomplished in such a short time. The company's unique technology platform positively impacts the planet and provides farmers with a natural and efficient solution to address the challenges of climate change. I am looking forward to work alongside the team as it accelerates its growth," said Pam Marrone.

    Johan de Saegher added, "It is an honor to join Elicit Plant's Board of Directors and contribute to building the company into a large scale and profitable enterprise as it is entering its next phase of development. Through its high value solutions, Elicit Plant offers for row crops a new dimension in abiotic stress management such as drought, safeguarding the yield of the farmer by optimizing the natural response of the plants to the changing environment."

    Jean-François Dechant, Chief Executive Officer and Cofounder of Elicit Plant, said: "Pam and Johan are a wonderful addition as Elicit Plant is entering new markets, expanding its laboratories and diversifying its portfolio of products. At such a strategic time for Elicit Plant, we are grateful for their confidence, and we are all eager to benefit from their knowledge and impressive track records."

    About Elicit Plant

    Elicit Plant is an agbiotech company created in 2017 with the ambition to become a sustainability transition champion in agriculture and respond to the global challenges of water stress in crops. Based in Charente (France), the firm has 60 employees across its R&D Center established within a 1,000 ha farm, its offices in Lyon, and its subsidiary in Brazil. Elicit Plant's proprietary technology is delivered through foliar application of phytosterols, molecules found in plants that reduce crops' water consumption. Open-field trials have shown an average yield increase of +10 bushels per acre on average. In 2022, Elicit Plant began marketing its BEST-a product line for corn crops in France, and obtained market approvals for Ukraine and Brazil.

    For more information: www.elicit-plant.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005582/en/

    Get the next $ATNF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

    Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

    9/15/21 7:48:59 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    12/18/23 4:15:16 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy

    Company announces new ticker (formally ATNF) and will begin trading on NASDAQ under ETHZ on August 18, 2025 Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million PALM BEACH, Fla., Aug. 18, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), (the "Company" or "ETHZilla"), today announced the official launch of its new brand as part of the Company's transition to focus on its recently announced Ethereum treasury strategy. Previously operating as 180 Life Sciences Corp., ETHZilla will focus a significant portion of its non-legacy operations on becoming an accumulation vehicle for Ether (ETH) that is built for the

    8/18/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences (ETHZilla) Holds 82,186 ETH

    Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif., Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million. In addition to the ETH, ETHZilla holds approximately $238 million in USD cash equivalents. "At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week, and

    8/12/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings This milestone follows the announcement of the Company's recently closed $425 million private placement PALO ALTO, Calif., Aug. 11, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), today announced that it has sold approximately $156 million aggregate principal amount of senior secured convertible notes due 2028 (the "Convertible Notes") in a private offering to an institutional investor on August 8, 2025. The Company intends to us

    8/11/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by 180 Life Sciences Corp.

    SCHEDULE 13D/A - ETHZilla Corp (0001690080) (Subject)

    8/18/25 5:22:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    8/18/25 8:01:32 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K/A - ETHZilla Corp (0001690080) (Filer)

    8/18/25 6:33:10 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Former 10% Owner Elray Resources, Inc. sold $9,278,586 worth of shares (2,998,000 units at $3.09) and exercised 3,000,000 in-the-money shares at a strike of $1.68, increasing direct ownership by 0.15% to 1,320,000 units (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/18/25 5:27:22 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Rudisill Mcandrew

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 5:20:03 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Heter Crystal Jane

    3 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 4:15:12 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Leadership Updates

    Live Leadership Updates

    View All

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

    PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

    12/12/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

    PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

    12/4/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    10/18/24 5:00:02 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    2/14/24 3:27:19 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Financials

    Live finance-specific insights

    View All

    180 Life Sciences Corp. - Corporate Updates

    Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

    10/3/24 8:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care